Want to see IL:PPBT full AI Analyst Report?
Purple Biotech (PPBT) AI Stock Analysis
Top Page
Purple Biotech
(TASE:PPBT)
The overall score of 41 is very low, driven primarily by the company's fundamental financial weakness as a pre-revenue biotech with significant and ongoing losses. The lack of earnings and negative P/E ratio further depress the valuation score. Technicals are neutral and provide no positive catalyst. The only mitigating factor is the company's low debt on the balance sheet, which offers some financial flexibility but is insufficient to offset the severe operational and valuation risks.
Purple Biotech (PPBT) vs. iShares MSCI Israel ETF (EIS)
- Market Cap
- ILS 32.37M
- Dividend Yield
- ―
- Average Volume (3M)
- 93.82K
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 0.17
- Revenue Growth
- ―
- EPS Growth
- -125.74%
- Country
- Israel
- Employees
- 10
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Purple Biotech Business Overview & Revenue Model
Company Description
Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies for cancer patients in the United States, specifically addressing challenges like tumor immune evasion and drug resistance. Its diverse oncology pipeline includes CM24, a...
How the Company Makes Money
Purple Biotech’s revenue model is primarily partnership- and licensing-based rather than product-sales-based, as it is a clinical-stage company and does not have a broad portfolio of commercialized products (commercial product revenue: null). The com...
Purple Biotech Financial Statement Overview
Summary
Financial performance is critically weak. The company is pre-revenue with no meaningful income, deeply negative margins, and consistent net losses widening to $24.4M TTM. Cash flow is poor with a -$7.7M TTM free cash flow, though the burn rate is slowing. The only relative strength is a clean balance sheet with negligible debt, but equity is rapidly eroding. Overall, the financial profile is precarious and entirely dependent on future pipeline success.
Income Statement
1Very NegativeBalance Sheet
55NeutralCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 195.80K | 0 | 0 |
| Gross Profit | -177.19K | -219.74K | -62.00K | -196 | -120 | -55 |
| EBITDA | -5.88M | -26.25M | -7.05M | -19.72M | -21.49M | -17.52M |
| Net Income | -24.41M | -26.39M | -7.24M | -19.88K | -21.67M | -18.38M |
Balance Sheet | ||||||
| Total Assets | 14.17M | 17.58M | 37.04M | 44.30M | 54.62M | 70.20M |
| Cash, Cash Equivalents and Short-Term Investments | 6.11M | 9.58M | 8.52M | 15.41M | 32.11M | 47.20M |
| Total Debt | 134.00K | 244.05K | 183.00K | 351.00K | 515.00K | 749.00K |
| Total Liabilities | 1.94M | 7.91M | 4.13M | 10.01M | 7.52M | 5.09M |
| Stockholders Equity | 12.27M | 9.72M | 32.86M | 34.21M | 46.91M | 64.83M |
Cash Flow | ||||||
| Free Cash Flow | -7.71M | -5.95M | -14.37M | -19.93M | -16.96M | -15.19M |
| Operating Cash Flow | -7.60M | -5.95M | -14.37M | -19.93M | -16.73M | -15.07M |
| Investing Cash Flow | 142.71K | 482.78K | 509.00K | 13.88M | 19.91M | 13.41M |
| Financing Cash Flow | 7.86M | 6.88M | 6.77M | 5.45M | 1.11M | 1.51M |
Purple Biotech Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:PPBT, the sentiment is Negative. The current price of 1.00 is above the 20-day moving average (MA) of 1.00, equal to the 50-day MA of 1.00, and below the 200-day MA of 1.02, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 40.89 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:PPBT.
Purple Biotech Risk Analysis
Purple Biotech disclosed 77 risk factors in its most recent earnings report. Purple Biotech reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksPurple Biotech Peers Comparison
Overall Rating
- IL:PPBT41Neutral
IL:BLRX41Neutral
IL:CANF37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| IL:PPBT | 41Neutral | ILS 32.42M | -0.01 | ― | ― | ― | -125.74% |
| IL:BLRX | 41Neutral | ILS 29.87M | -1.03 | ― | ― | -93.07% | 62.25% |
| IL:CANF | 37Underperform | ILS 15.98M | -0.24 | ― | ― | ― | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IL:PPBT | Purple Biotech Ltd. | 1.00 | -0.30 | -23.08% | |
| IL:XTLB | XTL Biopharmaceuticals Ltd. | 1.40 | -2.50 | -64.10% | |
| IL:CBI | Clal Biotechnology Industries Ltd | 22.90 | -8.30 | -26.60% | |
| IL:BLRX | BioLineRX Ltd. | 1.00 | -1.00 | -50.00% | |
| IL:CANF | Can-Fite BioPharma Ltd. | 263.30 | 262.30 | 26230.00% | |
| IL:MTLF | Matricelf Ltd. | 256.70 | -152.40 | -37.25% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 19, 2026